ダウンロード数: 159
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| s41467-018-04011-3.pdf | 2.42 MB | Adobe PDF | 見る/開く |
| タイトル: | Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells |
| 著者: | Allison, Thomas F. Andrews, Peter W. Avior, Yishai Barbaric, Ivana Benvenisty, Nissim Bock, Christoph Brehm, Jennifer Brüstle, Oliver Damjanov, Ivan Elefanty, Andrew Felkner, Daniel Gokhale, Paul J. Halbritter, Florian Healy, Lyn E. Hu, Tim X. Knowles, Barbara B. Loring, Jeanne F. Ludwig, Tenneille E. Mayberry, Robyn Micallef, Suzanne Mohamed, Jameelah S. Müller, Franz-Josef Mummery, Christine L. Nakatsuji, Norio Ng, Elizabeth S. Oh, Steve K. W. O’Shea, Orla Pera, Martin F. Reubinoff, Benjamin Robson, Paul Rossant, Janet Schuldt, Bernhard M. Solter, Davor Sourris, Koula Stacey, Glyn Stanley, Edouard G. Suemori, Hirofumi   https://orcid.org/0000-0002-3565-3111 (unconfirmed)Takahashi, Kazutoshi Yamanaka, Shinya  |
| 著者名の別形: | 中辻, 憲夫 末盛, 博文 高橋, 和利 山中, 伸弥 |
| 発行日: | 15-May-2018 |
| 出版者: | Springer Nature |
| 誌名: | Nature Communications |
| 巻: | 9 |
| 論文番号: | 1925 |
| 抄録: | The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC’s malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs. |
| 著作権等: | © The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| URI: | http://hdl.handle.net/2433/235744 |
| DOI(出版社版): | 10.1038/s41467-018-04011-3 |
| PubMed ID: | 29765017 |
| 出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。